A fluorescence-based opsonophagocytosis assay to measure the functional activity of antibody to group B streptococcus

Human Vaccines

Volumn 5, Issue 7, 2009, Pages 461-466

  Guttormsen, Hilde Kari ^a   Mascuch, Samantha J ^a   West, Julia C ^a   Paoletti, Lawrence C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Fluorescence; Glycoconjugate vaccines; Group B streptococcus; HL 60 cells; Opsonophagocytosis assay

Indexed keywords

COMPLEMENT; MICROSPHERE;

ANIMAL EXPERIMENT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN SPECIFICITY; ARTICLE; CELL STRAIN HL 60; CONTROLLED STUDY; EFFECTOR CELL; FLUORESCENCE ANALYSIS; FLUORESCENCE BASED OPSONOPHAGOCYTOSIS ASSAY; HUMAN; HUMAN CELL; IMMUNOASSAY; INTERMETHOD COMPARISON; NONHUMAN; OPSONIZATION; PHAGOCYTOSIS; STREPTOCOCCUS AGALACTIAE;

EID: 70349545800     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.8376     Document Type: Article

References (11)

1. Johri AK, Paoletti LC, Glaser P, Dua M, Sharma PK, Grandi G, Rappuoli R. Group B Streptococcus: global incidence and vaccine development. Nat Rev 2006; 4:932-42.
2. Clinicaltrials.gov. http://www.clinicaltrials.gov/ct2/show/ NCT00645346?term=group+B+Streptococcus&rank=3. Accessed 2009.
3. Madoff LC, Paoletti LC, Kasper DL. Surface structures of group B streptococci important in human immunity, In: Fischetti VA, Novick RP, Ferretti JJ, Portnoy DA, Rood JI, eds. Gram-positive pathogens. Washington D.C.: ASM Press 2006; 169-85.
4. Paoletti LC, Kasper DL. Glycoconjugate vaccines to prevent group B streptococcal infections. Expert Opin Biol Ther 2003; 3:975-94.
5. Schrag SJ, Zywicki S, Farley MM, Reingold AL, Harrison LH, Lefkowitz LB, et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med 2000: 342:15-20.
6. Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A. Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep 2002; 51:1-22.
7. Baltimore RS, Kasper DL, Baker CJ, Goroff DK. Antigenic specificity of opsonophagocytic antibodies in rabbit anti-sera to group B streptococci. J Immunol 1977; 118:673-8.
8. Guttormsen HK, Liu Y, Paoletti LC. Functional activity of antisera to group B streptococcal conjugate vaccines measured with an opsonophagocytosis assay and HL-60 effector cells. Human Vacc 2008; 4:370-4.
9. Yang HH, Mascuch SJ, Madoff LC, Paoletti LC. Recombinant group B Streptococcus alpha-like protein 3 is an effective immunogen and carrier protein. Clin Vaccine Immunol 2008; 15:1035-41.
10. Burton RL, Nahm MH. Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol 2006; 13:1004-9.
11. Paoletti LC, Guttormsen HK, Christian MS, Hoberman AM, McInnes P. Neither antibody to a group B streptococcal conjugate vaccine nor the vaccine itself is teratogenic in rabbits. Human Vacc 2008; 4:435-43.